| P50 | author | Mika Kähönen | Q29839349 |
| P2093 | author name string | Uusitalo H | |
| | Mäenpää J | |
| | Lehtimäki T | |
| | Nieminen T | |
| | Ropo A | |
| P2860 | cites work | Association between low plasma levels of ophthalmic timolol and haemodynamics in glaucoma patients. | Q53855923 |
| | Comparison of a new beta adrenergic blocker (MK 950) and propranolol in man. | Q54500339 |
| | Improved systemic safety and risk–benefit ratio of topical 0.1% timolol hydrogel compared with 0.5% timolol aqueous solution in the treatment of glaucoma | Q57417579 |
| | Polymorphisms of genes CYP2D6, ADRB1 and GNAS1 in pharmacokinetics and systemic effects of ophthalmic timolol. A pilot study | Q57417587 |
| | Cardiovascular effects of ophthalmic 0.5% timolol aqueous solution and 0.1% timolol hydrogel | Q57417600 |
| | Pharmacogenomics and drug response in cardiovascular disorders | Q28171051 |
| | Beta-blocker eyedrops and nocturnal arterial hypotension | Q28373592 |
| | Ocular and cardiovascular response to topical carteolol 2% and timolol 0.5% in healthy volunteers | Q33646125 |
| | Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future | Q34310938 |
| | Timolol metabolism and debrisoquine oxidation polymorphism: a population study | Q34397032 |
| | Randomised, controlled trial of spirometric changes in elderly people receiving timolol or betaxolol as initial treatment for glaucoma | Q35303647 |
| | Effects of glaucoma medications on the cardiorespiratory and intraocular pressure status of newly diagnosed glaucoma patients | Q35315104 |
| | Timolol: a preliminary report of its pharmacological properties and therapeutic efficacy in angina and hypertension | Q39590399 |
| | A comparison of timolol and propranolol in essential hypertension | Q40307647 |
| | Comparison of aqueous and gellan ophthalmic timolol with placebo on the 24-hour heart rate response in patients on treatment for glaucoma | Q42663676 |
| | Effect of timolol 0.5% gel and solution on pulmonary function in older glaucoma patients | Q43665557 |
| | Plasma timolol concentrations of timolol maleate: timolol gel-forming solution (TIMOPTIC-XE) once daily versus timolol maleate ophthalmic solution twice daily | Q43777796 |
| | Comparison of the cardiovascular effects of unoprostone 0.15%, timolol 0.5% and placebo in healthy adults during exercise using a treadmill test | Q44024289 |
| | Cardiovascular effects of timolol maleate, brimonidine or brimonidine/timolol maleate in concomitant therapy | Q44024291 |
| | Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension | Q45183545 |
| | Pharmacokinetic and pharmacodynamic analysis of systemic effect of topically applied timolol maleate ophthalmic gelling vehicle (Rysmon TG). | Q46601347 |
| | Efficacy and systemic side-effects of topical 0.5% timolol aqueous solution and 0.1% timolol hydrogel | Q46882133 |
| P433 | issue | 2 | |
| P304 | page(s) | 237-245 | |
| P577 | publication date | 2007-01-01 | |
| P1433 | published in | Scandinavian Journal of Clinical and Laboratory Investigation | Q15760785 |
| P1476 | title | Ophthalmic timolol: plasma concentration and systemic cardiopulmonary effects | |
| P478 | volume | 67 | |